体外心肺复苏用于院外心脏骤停的成本效果:多中心前瞻性队列研究
本研究基于SAVE-J前瞻性观察研究构建决策树模型(急性期)联合Markov模型(长期随访),估算难治性室颤/无脉性室速院外心脏骤停患者接受ECPR或传统CPR的终生成本与结局,主要结局为质量调整生命年(QALY)。ECPR的增量成本为¥3,521,189(€30,227),增量效果为1.34 QALY,增量成本效果比为¥2,619,692(€22,489)/QALY。确定性敏感性分析显示模型对ECPR后脑功能分级1级的概率、患者年龄及改良Rankin量表0分的长期医疗成本最敏感。概率敏感性分析显示在¥5,000,000支付意愿阈值下ECPR具成本效果的概率为86.7%。结论认为ECPR是经济上可接受的心脏骤停复苏策略,结果在考虑所有参数不确定性时仍稳健。
要点
- 针对院外心脏骤停且为难治性室颤/无脉性室速的患者,ECPR较传统CPR增量成本¥3,521,189(€30,227),增量效果1.34 QALY。
- 增量成本效果比为¥2,619,692(€22,489)/QALY,在支付意愿阈值¥5,000,000下ECPR具成本效果的概率为86.7%。
- 确定性敏感性分析显示结果最敏感于ECPR后脑功能分级1级的概率(¥2,153,977/QALY至¥3,186,475/QALY)、患者年龄(¥2,170,112/QALY至¥3,334,252/QALY)及改良Rankin量表0分的长期医疗成本(¥2,280,352/QALY至¥2,855,330/QALY)。
- 作者结论认为ECPR是经济上可接受的复苏策略,即使考虑所有参数的不确定性,结果仍稳健。
适用人群与场景
- 院外心脏骤停且为难治性室颤/无脉性室速的患者,模型基于SAVE-J前瞻性观察研究。
研究设计与关键结果
- 研究类型为基于前瞻性观察研究(SAVE-J)的经济学评价,构建决策树模型(急性期)联合Markov模型(长期随访),比较ECPR与传统CPR的终生成本与结局,主要结局为QALY。
- ECPR较传统CPR:增量成本¥3,521,189(€30,227),增量效果1.34 QALY,增量成本效果比¥2,619,692(€22,489)/QALY。
- 确定性敏感性分析:ECPR后脑功能分级1级的概率使ICER在¥2,153,977/QALY至¥3,186,475/QALY之间变动;患者年龄使ICER在¥2,170,112/QALY至¥3,334,252/QALY之间变动;改良Rankin量表0分的长期医疗成本使ICER在¥2,280,352/QALY至¥2,855,330/QALY之间变动。
- 概率敏感性分析:在支付意愿阈值¥5,000,000下,ECPR具成本效果的概率为86.7%。
- 作者结论认为ECPR是经济上可接受的复苏策略,且结果在考虑所有参数不确定性时仍稳健。
证据类型、等级与局限
- 证据类型:基于前瞻性观察研究(SAVE-J)的经济学评价(决策模型联合Markov模型),并进行了确定性敏感性分析与概率敏感性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为ECPR是经济上可接受的复苏策略,此结论基于难治性室颤/无脉性室速院外心脏骤停人群的模型分析,并在支付意愿阈值¥5,000,000下具成本效果概率86.7%。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: Extracorporeal cardiopulmonary resuscitation (ECPR) is an evolving resuscitative method for refractory cardiopulmonary arrests. However, considering the substantial healthcare costs and resources involved, there is an urgent need for a full economic evaluation. We therefore assessed the cost-effectiveness of ECPR for refractory ventricular fibrillation/pulseless ventricular tachycardia (VF/pVT).
METHODS: We developed a decision model to estimate lifetime costs and outcomes for out-of-hospital cardiac arrest patients with VF/pVT who received either ECPR or conventional cardiopulmonary resuscitation. Quality-adjusted life-years (QALY) was used as the main outcome measure. This model was a combination of a decision tree model for the acute phase based on a prospective observational study (SAVE-J study), together with a Markov model for long-term follow-up periods extrapolated from published data. To evaluate the robustness of this model, we conducted a comprehensive deterministic sensitivity analysis (DSA) and a probabilistic sensitivity analysis (PSA).
RESULTS: ECPR was cost-effective, with an incremental cost of ¥3,521,189 (Є30,227), an incremental effectiveness of 1.34 QALY, and an incremental cost-effectiveness ratio of ¥2,619,692 (Є22,489) per QALY gained. DSA revealed that the present model was most sensitive to probability of Cerebral Performance Category 1 after ECPR (¥2,153,977/QALY to ¥3,186,475/QALY), patient age (¥2,170,112/QALY to ¥3,334,252/QALY), and long-term medical cost for modified Rankin Scale 0 (¥2,280,352/QALY to ¥2,855,330/QALY). PSA indicated ECPR to be cost-effective and below the willingness-to-pay threshold of ¥5,000,000 with an 86.7 % possibility.
CONCLUSIONS: ECPR was an economically acceptable resuscitative strategy, and the results of the present study were robust even when considering the uncertainty of all parameters.
参考来源
- Matsuoka Y, Goto R, Atsumi T, et al. Cost-effectiveness of extracorporeal cardiopulmonary resuscitation for out-of-hospital cardiac arrest: A multi-centre prospective cohort study. Resuscitation. 2020. PMID: 33080369. doi:10.1016/j.resuscitation.2020.10.009
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。